ERBB2 and breast carcinoma: In vitro studies have, however, demonstrated that a combination of trastuzumab and 17-AAG led to enhanced down-regulation due to lysosomal degradation of ErbB2 in ErbB2-overexpressing breast cancer cell lines [20].